The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: 1

2

Rationale, Design and Operations

3

4 Authors:

- 5
- D. Clark Files^{1#}, Michael A. Matthay², Carolyn S. Calfee², Neil Aggarwal³, Adam L. Asare⁴, Jeremy R. Beitler⁵, Paul A. Berger III⁶, Ellen L. Burnham³, George Cimino⁴, Melissa H. 6
- 7
- Coleman², Alessio Crippa⁷, Andrea Discacciati⁷, Sheetal Gandotra⁸, Kevin W. Gibbs¹, Paul T. 8
- Henderson⁴, Caroline A.G. Ittner⁹, Alejandra Jauregui², Kashif T. Khan¹⁰, Jonathan L. Koff¹¹, 9
- Julie Lang¹⁰, Mary LaRose¹, Joe Levitt¹², Ruixiao Lu⁴, Jeffrey D. McKeehan³, Nuala J. Meyer⁹, 10
- Derek W. Russell⁸, Karl W. Thomas¹, Martin Eklund⁷, Laura J. Esserman², Kathleen D. Liu² on 11
- behalf of the ISPY COVID Adaptive Platform Trial Network¹³ 12
- 13
- ¹ Wake Forest School of Medicine, Winston-Salem NC USA 14
- ² University of California San Francisco, San Francisco, CA, USA 15
- ³ University of Colorado, School of Medicine, Aurora, CO, USA 16
- 17 ⁴ Quantum Leap Healthcare Collaborative, San Francisco, CA, USA
- ⁵ Columbia University, Irving Medical Center, New York, NY, USA 18
- ⁶ Sanford Medical Center, Sioux Falls, SD, USA 19
- 20 ⁷ Karolinska Institutet, Stockholm, Sweden
- ⁸ University of Alabama at Birmingham, Birmingham, AL, USA 21
- ⁹ University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA 22
- ¹⁰ University of Southern California, Los Angeles, CA, USA 23
- 24 ¹¹Yale School of Medicine, New Haven, CT, USA
- ¹² Stanford Healthcare, Stanford, CA, USA 25
- ¹³ Collaborating authors listed in appendix 26
- [#] corresponding author 27
- 28

29 Corresponding author contact information:

- 30 D. Clark Files MD
- Medical Center Blvd 31
- 32 Wake Forest School of Medicine
- 33 Winston-Salem NC USA 27157
- 34 clark.files@wakehealth.edu
- 35

36 Study sponsor contact information:

- 37 Paul Henderson PhD
- 38 Quantum Leap Healthcare Collaborative
- 39 499 Illinois Street
- San Francisco CA 94158 40
- p.henderson@quantumleaphealth.org 41
- 42
- 43
- 44
- 45

46 Abstract

Introduction. The COVID-19 pandemic brought an urgent need to discover novel effective
therapeutics for patients hospitalized with severe COVID-19. The ISPY COVID trial was
designed and implemented in early 2020 to evaluate investigational agents rapidly and
simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale,
implementation, and challenges of the ISPY COVID trial during the first phase of trial activity
from April 2020 until December 2021.

53

54 Methods and analysis. The ISPY COVID Trial is a multi-center open label phase 2 platform 55 trial in the United States designed to evaluate therapeutics that may have a large effect on 56 improving outcomes from severe COVID-19. The ISPY COVID Trial network includes academic 57 and community hospitals with significant geographic diversity across the country. Enrolled 58 patients are randomized to receive one of up to four investigational agents or a control and are 59 evaluated for a family of two primary outcomes-time to recovery and mortality. The statistical 60 design uses a Bayesian model with "stopping" and "graduation" criteria designed to efficiently 61 discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each 62 investigational agent arm enrolls to a maximum of 125 patients per arm and is compared to 63 concurrent controls. As of December 2021, 11 investigational agent arms had been activated, 64 and 8 arms were complete. Enrollment and adaptation of the trial design is ongoing.

65

Ethics and dissemination. ISPY COVID operates under a central institutional review board via
Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in
peer reviewed medical journals.

69

70 **Trial registration number**. Clinicaltrials.gov registration number NCT04488081

71

/3	Strengths and limitations of this study
74	The ISPY COVID Trial was developed in early 2020 to rapidly and simultaneously
75	evaluate therapeutics for severe COVID-19 on an adaptive open label phase 2 platform
76	The ISPY COVID Adaptive Platform Trial Network is an academic-industry partnership
77	that includes academic and community hospitals spanning a wide geographic area
78	across the United States
79	Of December 2021, 11 investigational agent arms have been activated on the ISPY
80	COVID Trial Platform
81	The ISPY COVID Trial was designed to identify therapeutic agents with a large clinical
82	effect for further testing in definitive efficacy trials—limitations to this approach include
83	the risk of a type 2 error
84	
85	
86	
87	
88	
89	
90	
91	
92	
93	
94	
95	
96	

97 Introduction

Despite decades of promising pre-clinical studies and large well-organized clinical trials, the 98 99 discovery of effective pharmacotherapeutics in critically ill patients has been exceedingly rare. 100 The COVID-19 pandemic brought an unprecedented level of attention and urgency to uncover 101 therapies for severe acute respiratory failure and acute respiratory distress syndrome (ARDS) 102 related to COVID-19. New approaches to critical care clinical trials that may rapidly screen 103 potentially effective therapies are urgently needed.¹ In the early phase of the pandemic, in the 104 winter of 2019-2020, global efforts were made to establish clinical trials and trial networks to 105 investigate therapies for COVID-19. In this report, we describe the I-SPY COVID Trial, a phase 106 2 adaptive platform randomized trial in the United States designed to test and identify drugs with 107 a large impact on improving recovery of hospitalized patients with severe COVID-19. This report 108 focuses on the (1) trial rationale and background, (2) design, (3) operations, (4) statistical plan, 109 (5) challenges and limitations of this approach in the context of the evolving COVID-19 110 pandemic during 2020-2021. This report focuses on the initial design of the ISPY COVID Trial 111 and reflects the study protocol conduct from initial implementation in April 2020 through 112 December 31st 2021.

113

114 Methods and Analysis

115 Design: Rationale, Background, Eligibility Criteria and Exclusions

116 The I-SPY COVID Trial was inspired in large part by the I-SPY 2 Trial, a phase 2 adaptive

117 platform clinical trial designed to discover novel treatments for patients with early-stage breast

- 118 cancer with high risk for early recurrence.² The I-SPY COVID Trial is a phase 2, multi-center,
- 119 multi-arm, adaptive, open-label, randomized controlled trial designed to rapidly screen agents to

identify those with potential impact to meaningfully improve outcomes for severe COVID-19

patients (Figure 1). Patients with confirmed COVID-19 and a modified World Health

- 122 Organization COVID-19 level of ≥5 (defined here as requiring ≥ 6L/min nasal oxygen) who meet
- 123 none of the exclusion criteria are eligible for the interventional and observational arms of the trial
- 124 (Table 1 & Figure 2). Initially, time to recovery (defined as reaching COVID-19 level ≤4 for at
- 125 least two consecutive days) was the primary endpoint, and overall mortality a key secondary
- 126 endpoint (Supplemental Table 1). Following discussions with the Data Monitoring Committee

Table 1. Master Inclusion Exclusion Criteria of the ISPY COVID Platform Trial

Inclusion (must meet all)

- Age \geq 18 years of age
- Admitted to the hospital and treated with high flow oxygen (≥ 6liters nasal cannula or mask delivery) or intubated and mechanically ventilated for the treatment of established or presumed COVID-19
- Informed consent signed by patient or proxy
- Confirmation of SARS-CoV-2 infection by PCR or antigen testing prior to randomization

Exclusion (any single excludes patient from trial)

- Pregnant or breastfeeding
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agent based on review of medical record and patient history
- Comfort measures only
- Acute or chronic liver disease with a Child-Pugh score > 11
- Resident for more than six months at a skilled nursing facility
- Estimated mortality greater than 50% over the next six months from underlying chronic conditions
- Time since requirement for high flow oxygen or mechanical ventilation greater than 5 days
- Anticipated transfer to another hospital which is not a study site expected within 72 hours
- End-stage kidney disease or acute kidney injury requiring dialysis
- Co-enrolled in another clinical trial of a pharmacologic agent with an Investigational New Drug (IND) assignment
- and the Food and Drug Administration, mortality was combined with time to recovery as a family
- 128 of two primary endpoints on January 15th 2021.
- 129
- 130 Design: Study Backbone and Investigational Agent Selection
- 131 Patients who meet inclusion/exclusion criteria are randomized to backbone therapy alone (the
- 132 control arm) or backbone therapy plus 1 of up to 4 investigational agents or agent combinations.
- 133 The initial backbone treatment for the trial was assigned following review of data that emerged

in mid 2020 on the use of remdesivir and dexamethasone for COVID-19 from separate clinical
trials.³⁴ During the conduct of the trial, the investigators have regularly re-evaluated the
selection and dosing of dexamethasone, remdesivir and other potential therapies as new data
has become available. As new therapies became available for COVID-19 (e.g. baricitinib and
tocilizumab) during the conduct of the trial, the case report forms were modified to capture the
clinical use of these concomitant medications.

140

141 The I-SPY COVID Agents Committee was formed to develop a process for evaluation of 142 potential agents into the I-SPY COVID Trial. Overall agent prioritization is based on the 143 estimated assessment of likelihood to reduce mortality and time to recovery. More specific rank 144 criteria include a range of biologic, logistical and safety considerations as well as manufacturing 145 supply chain capability (Table 2). In addition to these characteristics, practical considerations 146 relate to the adaptive trial design, available resources for funding the testing of the therapy, and 147 an accelerated timeline of the public health crisis. These selection criteria include a requirement 148 for minimal drug-specific patient exclusions and low risk for drug-drug interactions in critically ill 149 patients. High priority is assigned to the presence of a sufficient drug supply and mechanism to 150 rapidly scale up drug production to reach a large population if treatment efficacy is established. 151 When agents with overlapping mechanisms of action are considered, priority is assigned to one 152 agent in that class that ranks higher in other rank criteria in order to avoid testing multiple 153 agents within a single biologic pathway.

154

- 155 Members of the Agents Committee with complementary expertise in acute lung injury, critical
- 156 illness, and pharmacology evaluate each potential agent and present the higher priority
- 157 candidate agents to the entire investigator group. In some instances, staff from the
- 158 manufacturing company of potential agents are invited to present data directly to the
- 159 investigators. However, company representatives are excluded from all follow-up deliberations
- and decisions on inclusion of the agent in the trial. In these subsequent discussions, pro- and

Table 2. Agent Selection Criteria

- Mechanism of action and biologic plausibility
- Approved drug indications and dosing
- Safety and efficacy in established use and approved indications
- Expected safety and toxicity in patients with critical illness and hypoxemia
- Adverse events of special interest
- Drug-specific exclusion criteria
- Drug-drug interactions
- Proposed trial dose, route of administration, duration of treatment
- Dose adjustment requirements and drug discontinuation criteria
- Available drug supply and production capacity
- 161 con- arguments are developed and priorities for additional background research established. In

twice-monthly follow-up reviews, the investigator group reaches consensus-based decisions on

163 whether or not the agent should be included in the trial.

164

Throughout the agent review process, individual investigators voluntarily identify agents to 165 166 support in the trial and serve as agent "chaperones" for the duration of the trial. Each agent is 167 assigned two to three investigator chaperones. If the agent is selected for inclusion, the 168 chaperones prepare the materials necessary for IRB approval and implementation, including 169 agent-specific appendices to the master protocol, informed consent documents and technical 170 guides on dosing and administration. Chaperones work closely with the clinical trial operations 171 group to nest the agent appropriately in the context of the I-SPY Trial platform. Chaperones 172 remain available to study site personnel throughout the treatment period to provide assistance 173 on dosing, side effects and technical issues. The common inclusion/exclusion criteria of the 174 platform necessitate minimizing agent-specific exclusion criteria. Therefore, significant efforts 175 are made by chaperones and agent sponsors to streamline and eliminate as many as possible 176 agent-specific exclusions. In instances where agent-specific exclusions become numerous, thus 177 limiting the generalizability of the agent, the proposed agent is not selected for placement on the 178 platform.

179

180 Investigative agents were initially identified through partnership with COVID-19 Research and Development Alliance (COVID-19 R&D),⁵ a consortium of research and development leaders in 181 182 industry formed to accelerate new COVID-19 therapies and vaccines. These initially proposed 183 agents were identified by COVID-19 R&D as having high probability of becoming successfully 184 repurposed for COVID-19 treatment. Of the 11 agents initially identified in this process, three 185 were selected for trial inclusion (apremilast, icatibant and cenicriviroc). Subsequent agents 186 were brought forward for consideration through direct communication to the Agents Committee 187 by trial investigators with expertise with a particular repurposed agent, by pharmaceutical 188 companies responding to the opening of the trial, the United States government as well as 189 informal contacts in academia. Between April 2020 and November 2021, over 70 individual

190	agents were reviewed in detail, including 12 that were included in 11 trial arms (one arm was a
191	combination of famotidine and celecoxib). Of the 8 completed arms, 5 were solicited by the
192	pharmaceutical industry and the remainder were nominated the United States government and
193	by trial investigators. A figure of the activated arms on the ISPY COVID trial from August 2020
194	through December 2021 are provided in Supplemental Figure 1 .
195	
196	Design: Patient and Public Involvement
197	The primary outcomes of the ISPY COVID Trial were designed to focus on patient-centered
198	outcomes. Both recovery of respiratory function and mortality are patient-centered endpoints.
199	Due to the urgent nature of the pandemic, no COVID-19 patients were included in the
200	development of the ISPY COVID Trial Protocol. The randomization followed by consent process
201	outlined in this manuscript was developed using the process employed in the ISPY 2 Trial ⁶ to
202	reduce burden on participants and surrogates. During the development of the ISPY COVID
203	Trial, this method was presented to the ISPY IRB Working group, which includes a patient
204	advocate. The ISPY IRB Working group found this method to be more patient-centered and
205	supported this method to be used in the ISPY COVID trial.
206	

207 Operations: Randomization and Consent

208 Up to four investigational agents can be active in I-SPY COVID at any given time. Patients are 209 randomly assigned with equal probability to receive any of the investigational agents, while a 210 higher proportion of participants are assigned to the backbone control arm. For instance, the 211 ratio of randomization is 1.4:1:1:11 for the control arm to the four investigational arms (the 212 ratios of control to interventional changes depending on the number of active agents in the 213 study, with ratios 1:1 with one active agent, 1.2:1:1 with two active agents, and 1.3:1:1:1 with 214 three active agents). Randomization is performed centrally and is stratified by site and modified 215 WHO COVID-19 status at study enrollment.

216

217	To facilitate a patient-centered consent process, randomization is performed prior to consent.
218	This order of the randomization and consent process has worked well in I-SPY 2 and has the
219	advantages of avoiding a two-step consent process and simplifying patient information.67 That
220	is, an individual patient interested in the trial only receives information about the one
221	investigational agent that they are randomized to receive (which could also be the control arm).
222	The disadvantage of this consent approach is that there is a risk of generating different accrual
223	patterns across the trial arms, due to different perceived risks by participants during consent.
224	Therefore accrual across arms must be closely monitored. Patients who do not consent to be
225	randomized enter an observational cohort (using an IRB-approved waiver of consent
226	mechanism), where disease outcomes and other endpoints are tracked. Patients with an agent-
227	specific exclusion to a study drug upon randomization move into the backbone control arm. The
228	study screening, randomization and consent process in relation to investigational drug arm,
229	control arm or observational arm is shown in Figure 2 .
230	
231	Rationale: The I-SPY COVID Trial-Endpoints and Open Label Design
232	We explicitly decided to focus on severe COVID-19, defined by clinical and physiologic criteria.
233	This rationale is reflected in the choice of the primary endpoints of the trial. Time to recovery
234	and mortality were thought to be important outcomes for managing the health crisis created by
235	the global pandemic; faster time to recovery helps to increase hospital bed availability and to
236	avoid hospital strain – a key objective during the pandemic. Mortality remains the optimal
237	primary outcome in the field of critical care; while modification of mortality is challenging to
238	achieve, it is still the most important patient-centered outcome.

239

Multiple reasons exist for the open label design for a phase 2 trial during the pandemic. Rapidlydeveloping and executing a platform trial, whereby multiple agents are tested simultaneously,

242 and new agents replace outgoing agents in succession, requires flexible study operations. 243 Because different agents in the platform will have different routes of administration, dosing 244 schedules, and durations, the use of placebos for each agent was deemed complex and 245 unwieldy, resulting in testing fewer active agents for COVID-19. Some platform trials have used 246 a pooled placebo concept, though this option remained impractical given the number of agents 247 that were planned to be rapidly tested during the pandemic. While the open-label approach 248 does potentially allow for investigator bias, a similar open label approach has also been used 249 successfully in the RECOVERY Platform for COVID-19 in the United Kingdom.⁸ 250 Ultimately, the open label design of the I-SPY COVID trial was deemed to be the most efficient 251 approach to rapidly and safely evaluate novel therapeutics for severe COVID-19, with the goal 252 that promising agents could be further tested in a closed, double blinded placebo-controlled 253 format upon trial graduation. Lastly, we chose to include a parallel observational cohort that 254 could be included to better understand demographics and outcomes of COVID-19 patients with 255 rapidly changing therapeutic standards and to provide generalizability against a non-study 256 population.

257

258 Design: Biomarkers and Biospecimen Collections

259 Severe COVID-19 is characterized by an inflammatory host response to the SARS-CoV-2 virus; 260 however, even within the group of patients with severe and critical COVID-19, there is potentially important biologic heterogeneity that may influence treatment response.⁹ The I-SPY 261 262 COVID trial was designed to collect key biospecimens from enrolled patients in order to permit 263 subsequent analyses of heterogenous treatment effect, to identify potentially important 264 mechanisms that relate to clinical outcomes, and enable pharmacokinetic evaluations of the 265 novel therapies being tested. Biospecimens include plasma and whole blood RNA (Days 1, 3 266 and 7), serum and peripheral blood mononuclear cells (PBMCs) (Days 1 and 7), urine (Days 1

267 and 3), and DNA (Day 1 only). Examples of the type of analyses that will be conducted include testing whether previously identified phenotypes of ARDS are relevant in COVID-19⁹, replicating 268 innovative analyses of immunotypes within severe COVID-19.¹⁰ testing for anti-Type I interferon 269 antibodies in serum from enrolled patients,¹¹ and measuring plasma viral antigen levels and 270 271 SARS-CoV-2 endogenous antibody levels. In addition to these exploratory biomarker analyses, 272 biomarkers measured in clinical labs at enrolling sites such as D-dimers, CRP, and the absolute 273 neutrophil count/absolute lymphocyte ratio are being recorded in order to test for prognostic 274 and/or predictive enrichment value.

275

276 Design: Statistical Analysis Plan

277 Bayesian survival regression models are used to model the hazard functions for the two events 278 of interest: (i) recovery (treating death as a competing event); and (ii) overall death. We used 279 Bayesian proportional-hazard Weibull models with weakly informative priors to model the cause-280 specific hazard function for recovery (treating death prior to recovery as a competing event) as a 281 function of study arm, adjusting for baseline COVID-19 level. Similarly, Bayesian proportional-282 hazard Weibull models were used to model the hazard function for all-cause mortality. 283 Importantly, concurrent controls are used so that the control group is chosen from the same 284 population as the investigational agent group over time given the potential of changing 285 background recovery and mortality rates in an evolving pandemic. The primary analyses are 286 performed on the intention-to-treat (ITT) population, which includes those randomized patients 287 who signed the informed consent.

288

Due to the randomization followed by consent process in this trial, the *a priori* analyses also include a *super ITT population*. This population consists of all randomized patients, regardless of whether they consented to receive the investigational agents or declined, thereby entering the

292	observational cohort. The super ITT population will thus not be impacted by the potential effect
293	of the randomization-consent process on the patient population in the different trial arms.

- 294
- 295 Design: Agent Graduation and Futility Boundaries

During the course of the trial, the effect of the treatments is evaluated every two weeks by the DMC. At these evaluations, treatments may "graduate" for superiority or be dropped for futility according to the following criteria:

- If at least 50 patients have been randomized and consented to a treatment arm and the
- 300 posterior probability is at least 0.975 that the cause-specific hazard ratio (csHR) for
- 301 recovery (investigational agent vs. control) is greater than one OR if the posterior
- probability is at least 90% that the hazard ratio for overall mortality is smaller than one,
- 303 the treatment is evaluated by the DMC for *graduation*.
- If at least 40 patients have been randomized and consented to a treatment arm and the
- 305 posterior probability is at least 0.9 that the csHR for recovery is less than 1.5 AND the
- 306 posterior probability is at least 50% that the hazard ratio for overall mortality is greater
- 307 than one, a treatment is evaluated by the DMC to be dropped for futility.

308 If the maximum sample size of 125 participants in a treatment arm is reached, assignments to

- that arm will end. If an investigational agent reaches a threshold for graduation or futility, the
- 310 DMC reviews the findings and make a recommendation to Study Principal Investigators (PIs) for
- final approval. In addition to examining hazard ratios for recovery and overall mortality, the DMC
- also reviews and evaluates cumulative incidence functions (**Figure 3**).
- 313
- 314 Design: Operating Characteristics—Type 1 and Type 2 Errors
- Prior to beginning the trial, study statisticians tested the trial's operating characteristics by
- simulating a large number of virtual trials under multiple scenarios. The type I error rate for an

317 individual Investigative Agent (probability to graduate a specific Investigational Agent despite no effect on reducing recovery or mortality rate) was estimated to be 4-5% when time to recovery 318 319 was used a single primary endpoint. After adding overall mortality to the primary endpoint 320 definition (to form a family of two primary endpoints, recovery and overall mortality), the type 1 321 error rate was estimated to up to 17% depending on simulated scenario, which was deemed 322 acceptable for a phase 2 signal seeking trial. The power to graduate an individual agent was 323 above 85% in scenarios where the csHR for recovery was set to 1.75. Similarly, the power for a 324 given individual investigational agent arm was greater than 85% if the HR for overall mortality 325 was below 0.5. Investigational Agents with more moderate effect sizes for recovery (csHRs of 326 1.5 or less or a HR for overall mortality of 0.7 or higher) graduated at lower rates (about 65% or 327 less).

328

329 Overall, these simulations indicate that the current graduation and futility rules may control 330 reasonably well the false graduation rates, while at the same time they might provide sufficient 331 power to graduate highly effective investigational agents. However, there are important 332 limitations to this approach including the risk of a type 2 error, due to small sample sizes, giving 333 limited power for smaller effect sizes. The design to use 40-125 patients in each group runs the 334 risk of discarding a potentially effective agent, ie a type 2 error. In prior phase 2 trials, wide 335 confidence intervals illustrate the potential for a type 2 error with a restricted number of patients, as discussed by Abraham and Rubenfeld regarding a phase 2 trial of sepsis.¹² With wide 336 337 confidence intervals and small numbers of patients, it is challenging to exclude harm or benefit. 338 Another example is the Brower trial of lung protective ventilation in 52 patients which showed no 339 benefit,¹³ but then the properly powered ARMA trial with 861 patients showed a major reduction in mortality.14 340

341

The I-SPY COVID Trial was designed early in the pandemic, and given the singular etiology of lung injury in patients with severe COVID-19, many investigators anticipated that ARDS from COVID-19 would exhibit less heterogeneity than "traditional" ARDS.¹⁵ While it remains unclear whether severe COVID-19 ARDS exhibits the degree of heterogeneity of ARDS in the pre-COVID-19 era,^{9 16} further biologic and clinical phenotyping may be necessary to find effective targeted therapies in a screening trial of this size and potentially re-evaluating the number of patients needed to evaluate candidate agents.

349

350 Operations: Real Time Data Entry and Reporting

351 A minimal set of key clinical and research outcome data elements were defined as part of the 352 daily checklist for enrolled participants (Figure 4). The "checklist" was implemented in 353 OpenClinica (Waltham, MA) Electronic Data Capture (EDC) system to support data entry for 354 subjects randomized to investigational agent arms or the observational cohort. Daily eCRFs are 355 completed from enrollment until discharge, with additional follow up consisting of electronic 356 Patient Reported Outcome (ePRO) survey questionnaires using HealthMeasures PROMIS© 357 and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse 358 Events (PRO-CTCAE[™]) validated instruments at day 28, 60 and 120.

359

360 Despite streamlining the data collection in I-SPY COVID, the pandemic strains on clinical and

361 research staff sometimes led to delays in data entry that were addressed on a site-specific basis

362 using remote staffing models (see "Novel Implementation Challenges" section below).

363 Limitations to a streamlined dataset include reduced granularity of exploring important

364 physiologic variables such as oxygenation index or plateau pressures, or the FiO₂ or flow rates

365 on patients enrolled being treated with high-flow nasal oxygen, which have important clinical

366 implications for patients with acute respiratory failure from severe lung injuries.

367

368 Operations: Safety

Clinical trials in critically ill patients share unique challenges for safety monitoring. Specifically, 369 370 study participants often possess significant comorbidities (i.e., chronic organ dysfunction, 371 immune suppression, and malignancy), receive numerous concomitant medications with 372 potential for interactions, and experience marked derangements in baseline physiology (i.e., 373 vital sign and laboratory abnormalities) relative to populations in which potential investigational 374 agents have previously been studied. These challenges are amplified for COVID-19 patients 375 where multisystem organ involvement is common but accurate baseline rates of complications 376 such as stroke, thrombosis, and cardiac dysfunction are yet to be established, and may vary 377 over time. Additionally, the usual care of these patients is a rapidly moving target. This topic is 378 particularly challenging for phase 2 trials in which there may be limited clinical experience for 379 investigational agents and even FDA-approved medications may be used at higher doses and in 380 combinations not previously studied. The open-label and shared control structure of the I-SPY 381 COVID platform trial is designed to allow for monitoring for known side effects and rapid testing 382 of multiple agents, but also creates potential for bias in adverse event reporting due to 383 differential scrutiny applied to study arms (i.e., monitoring for secondary infections in patients 384 randomized to an immunomodulatory agent or kidney injury for a potentially nephrotoxic agent 385 relative to shared controls). The I-SPY COVID platform has used several strategies to 386 overcome these challenges.

387

First, laboratory assessment of vital signs and organ dysfunction are collected daily and clinically important events (i.e., pulmonary embolism, deep venous thrombosis, and kidney injury) are systemically collected on daily report forms. This approach allows for systematic comparisons across therapy arms of event rates and organ failures rather than relying on investigator recognition and capture of these events (**Figures 4 and 5**). Second, I-SPY COVID has constituted a Safety Working Group (SWG) to provide an additional layer of structured

394 safety monitoring across all trials within the platform. The SWG provides real-time monitoring of 395 adverse events and provides guidance to the DMC on adverse event reporting. The SWG is led 396 by two critical care physicians not otherwise part of the clinical trial and also includes the drug 397 chaperones, study principal investigators, and operations committee chairs. This group meets 398 on a regular basis to review adverse events and to determine potential attribution to COVID-19 399 and/or to investigational agents. The SWG chairs also provide external review of severe 400 adverse events and other safety events that might require expedited reporting. Finally, the drug 401 chaperones serve as internal content experts for a given agent and are available to 402 investigators on a 24/7 basis to review potential events related to the investigational agent 403 regardless of expectedness. Reporting of potential events is encouraged so that these can be 404 formally reviewed by the Safety Working Group. Every death, AE, AESIs and SAE is reviewed 405 by the Safety Working Group to evaluate if the adverse event is expected for the investigational 406 agent, if expected with COVID-19 or ARDS, and likelihood of being caused by the 407 investigational agent. Adverse event reporting is configured using the Shiny R Studio. Lastly, 408 site conduct is audited by Quantum Leap Healthcare Collaborative and trial conduct by other 409 study sponsors.

410

411 Operations: Pharmacy

The investigational drug services (IDS) pharmacy plays a pivotal role in the ability to deploy agents safely and rapidly into a continuously running adaptive platform trial, such as I-SPY COVID. Careful planning and strong communication are paramount, but several additional key issues must be addressed to accomplish this efficiently. First, participating sites typically designate one lead and at least one back-up pharmacist at each site. Second, a consistent workflow (standard operating procedure) for the implementation of each new agent is established. This workflow includes centralized delivery of drug and trial arm-related

419 information, personnel training documentation procedures, and drug storage provisions. Third,

420 IDS pharmacists implement drug ordersets into the clinical workflows at each site.

421

Given the rapidity with which new agents enter the trial, pharmacy lead time and preparedness is important. Adequate lead-time is required to allow for the preparations mentioned above to be safely and smoothly executed. As such, for a trial of this nature in which study arms may drop out without warning and new arms quickly advance in the priority list, the coordinating center must ensure that all affiliated pharmacies are prepared for future agents before they are added to the trial.

428

429 For study sites that do not already have an Investigational Drug Services (IDS) Pharmacy, the 430 aforementioned recommendations are even more critical. In addition to those, it is also vital to 431 identify a pharmacist (and back-up) committed to overseeing the pharmaceutical aspects of the 432 study at both the community partner site and the supervising site. An electronic drug 433 accountability system that meets FDA requirements for investigational drugs is necessary to 434 allow for ease of monitoring for drug usage and storage. A remote (or in-person) visit from the 435 partnering IDS pharmacy can help ensure that drug storage conditions are appropriate and that 436 evaluation as well as documentation (e.g., of temperature controls) can be appropriately 437 conducted and any gaps in training, equipment, space, or hours of site pharmacy coverage or 438 expertise can be identified and addressed.

439

440 Additional Considerations: No established network or funding, contracting

To rapidly meet the short timeline of the pandemic, I-SPY COVID leveraged the efficiency and
infrastructure of the I-SPY 2 Trial, partnering with the not-for-profit sponsor, Quantum Leap
Healthcare Collaborative. One of the solutions to drive efficiency was to first activate sites that
already had existing I SPY 2 contracts. As well, we used the same contract for every site. All

445	pharma com	panies also	agree to	a single	contract.	The prior	r experience	with many	v of the

446 companies sped the process of working with companies. As well, the initial partnership with the

447 COVID R&D consortium established an example for how companies could work collaboratively

- 448 and quickly in a pandemic. Some sites (primarily those not familiar with I SPY 2) had longer
- delays with contracting and site activation. Establishing a central IRB was essential for this
- 450 process. The ISPY COVID trial is composed primarily of academic medical centers with
- 451 experience conducting critical care clinical trials. However, the group felt it important to also
- 452 include community sites, where most patients across the country receive care for COVID-19.
- 453 The group used hybrid approaches to activate and support community sites without significant
- 454 research infrastructure using different site involvement paradigms (**Table 3**).
- 455 **Table 3**. Community Site Infrastructure Paradigms in ISPY COVID

Types of hospitals	Status	Pharmacy	Coordinators	Compensation	Geographic
Academic or Community Centers with Research Capacity and Experience	I-SPY COVID site	Investigational Pharmacy	I-SPY COVID site	Full	NA
Academic or Community Centers with ICU care but Limited Research Infrastructure	Partnership with one of the I SPY COVID sites	Clinical Pharmacist trained by Investigational Pharmacy Partner	In partnership with one of the I-SPY COVID sites	Shared	NO
Community Hospitals without Sufficient ICU Care for Severe COVID-19	Transfer patients to nearby I SPY COVID site	Transfer to I- SPY Site	Partner with I-SPY site. Work to identify eligible patients and coordinate transfer	Shared	YES

456

457 Additional Considerations: Novel Implementation Challenges During the Pandemic

458 The alarming pace of the COVID-19 pandemic has placed substantial time pressure on

459 therapeutic trials.¹⁷ Hospitals surging with COVID-19 patients have potential to be the largest

460 contributors to trials. Yet, frequently, they are also the most resource-strained. Shortages of

- 461 such basic necessities as personal protective equipment (PPE), medications, and personnel
- 462 have occurred often.¹⁸ In many hospitals, investigators and clinical research staff with relevant
- 463 skills were reassigned to clinical duties. Several hospitals and universities, concerned for

anticipated revenue losses, instituted broad hiring freezes or required new arduous

administrative approvals to hire staff, which in some cases unintentionally impeded timely

466 scaling up of trial personnel.

467

To address these issues, I-SPY COVID took several innovative steps. The trial secured PPE for shipment to sites as needed, helping ensure trial procedures would not deplete PPE in hospitals facing extreme scarcity. To address potential medication shortages, the trial committed to providing an independent supply of backbone therapies received by all patients, which included remdesivir at the time of initial trial design.

473

474 Staffing shortages have been addressed in part by partnering with a healthcare staffing 475 company to hire off-site data entry specialists, freeing on-site staff to focus on patient accrual 476 and in-person study procedures during surges. This "rapid response" staffing model has the 477 added benefit of being able to reassign data entry specialists already familiar with the protocol 478 and case report forms to new locations as surges wax and wane among sites over time. To 479 overcome in-person research staff shortages, high-enrolling sites have engaged gualified. 480 approved clinical staff in the recruitment and consent process—embracing a shared mission of 481 expanding access to promising therapeutics and accelerating discovery, overcoming the 482 conventional clinical/research divide.

483

Each of the above sections includes comments on the challenges for the design and conduct of this I-SPY COVID platform trial during the COVID-19 pandemic. The investigators will consider future modifications to the protocol, including moving consent prior to randomization, decreasing the number of agents to be tested at the same time, reviewing the graduation and futility criteria, and the sample size as well as increasing the granularity of baseline systemic and respiratory data collection. The strengths and weaknesses of the open-label versus a placebo-controlled

490	design will also be evaluated. We now know that many factors contribute to heterogeneity of
491	COVID-19 disease severity in hospitalized patients so further consideration of ways to enhance
492	the database but maintain reasonable feasibility and efficiency will be evaluated.
493	
494	
495	Ethics and Dissemination
496	The trial procedures and protocols are regulated under a central IRB structure at the Wake
497	Forest School of Medicine. All patients (or designated surrogate) entering the portion of the trial
498	that receive an investigational agent undergo patient level consent by study staff and/or study
499	investigators. Protocol revisions are announced at weekly investigator and coordinator meetings
500	and are submitted to the FDA and IRB. No patient level data will be released, and all personal
501	information will remain confidential and de-identified. Results of the agents completing the ISPY
502	COVID Trial will be reported in press releases, scientific abstracts and manuscripts.
503	
504	
505	
506	
507	
508	
509	
510	
511	
512	
513	
514	

Contributorship Statement. DCF, MAM, CSC, NA, JRB, PAB, ELB, GC, SG, KWG, PTH,

KTK, JLK, JL, NJM, DWR, KWT, ME, LJE, KDL contributed to the study protocol design and drafting of the manuscript. ALA, MHC, JL, PTH, CAGI, AJ, ML, JDM, DCF, MAM, CSC, LJE, KDL contributed to the study operations. AC, AD, RL, ME, LE contributed to the statistical design. All authors reviewed and provided final edits. **Competing Interests.** DCF has received funding from Quantum Leap Healthcare Collaborative related to this work and from the National Institutes of Health unrelated to this work. DCF has worked as a consultant for Cytovale and Medpace unrelated to this work. ICJME forms from all authors will be uploaded. Funding. Effort was sponsored by Allergan, Amgen, Takeda Pharmaceutical Company, Implicit Bioscience, J&J, Pfizer, Roche/Genentech, Apotex, Omeros, the COVID-19 Research and Development Consortium, a FAST Grant from Emergent Venture George Mason University, the DoD Defense Threat Reduction Agency (DTRA). The Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) and the Grove Foundation. Effort was sponsored in part by the U.S. Government under Other Transaction number W15QKN-16-9-1002 between the MCDC and the Government. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government. Data Sharing Statement. Data generated from the ISPY COVID Trial will be made available in peer reviewed journals.

554 References

- 555 1. Goligher EC, Zampieri F, Calfee CS, et al. A manifesto for the future of ICU trials. 556 *Critical care* 2020;24(1):686. doi: 10.1186/s13054-020-03393-5 [published Online First: 557 2020/12/11]
- 558 2. Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of 559 investigational cancer drugs. Jama 2011;306(23):2608-9. doi: 10.1001/jama.2011.1837 560 [published Online First: 2011/12/22]
- 561 3. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 -Final Report. The New England journal of medicine 2020;383(19):1813-26. doi: 562 10.1056/NEJMoa2007764 [published Online First: 2020/05/24] 563
- 564 4. Group RC, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-565
- 19. The New England journal of medicine 2021;384(8):693-704. doi:
- 566 10.1056/NEJMoa2021436 [published Online First: 2020/07/18]
- 567 5. https://www.covidrdalliance.com.
- 6. Barker AD, Sigman CC, Kelloff GJ, et al. I-SPY 2: an adaptive breast cancer trial design 568 569 in the setting of neoadjuvant chemotherapy. *Clin Pharmacol Ther* 2009;86(1):97-100. doi: 10.1038/clpt.2009.68 [published Online First: 2009/05/15] 570
- 571 7. Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve 572 Outcomes in High-Risk Breast Cancer. Curr Breast Cancer Rep 2019;11(4):303-10. doi: 10.1007/s12609-019-00334-2 [published Online First: 2020/12/15] 573
- 574 8. Normand ST. The RECOVERY Platform. The New England journal of medicine 2021;384(8):757-58. doi: 10.1056/NEJMe2025674 [published Online First: 2020/07/25] 575
- 576 9. Sinha P, Calfee CS, Cherian S, et al. Prevalence of phenotypes of acute respiratory 577 distress syndrome in critically ill patients with COVID-19: a prospective observational study. The Lancet Respiratory medicine 2020;8(12):1209-18. doi: 10.1016/s2213-578 2600(20)30366-0 [published Online First: 2020/08/31] 579
- 580 10. Mathew D, Giles JR, Baxter AE, et al. Deep immune profiling of COVID-19 patients 581 reveals distinct immunotypes with therapeutic implications. *Science* 2020;369(6508) doi: 10.1126/science.abc8511 [published Online First: 2020/07/17] 582
- 11. Combes AJ, Courau T, Kuhn NF, et al. Global absence and targeting of protective 583 584 immune states in severe COVID-19. Nature 2021;591(7848):124-30. doi: 10.1038/s41586-021-03234-7 [published Online First: 2021/01/26] 585

586 587 588	12. Rubenfeld GD, Abraham E. When is a negative phase II trial truly negative? <i>American journal of respiratory and critical care medicine</i> 2008;178(6):554-5. doi: 10.1164/rccm.200807-1136ED [published Online First: 2008/08/30]
589 590 591 592	13. Brower RG, Shanholtz CB, Fessler HE, et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. <i>Critical care medicine</i> 1999;27(8):1492-8. doi: 10.1097/00003246-199908000-00015 [published Online First: 1999/09/02]
593 594 595	14. Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. <i>New England Journal of Medicine</i> 2000;342(18):1301-08. doi: doi:10.1056/NEJM200005043421801
596 597 598	15. Juschten J, Tuinman PR, Guo T, et al. Between-trial heterogeneity in ARDS research. Intensive care medicine 2021;47(4):422-34. doi: 10.1007/s00134-021-06370-w [published Online First: 2021/03/14]
599 600 601 602	16. Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. <i>The</i> <i>Lancet Respiratory medicine</i> 2020;8(12):1201-08. doi: 10.1016/s2213-2600(20)30370-2 [published Online First: 2020/08/31]
603 604 605	17. Lane HC, Fauci AS. Research in the Context of a Pandemic. <i>The New England journal of medicine</i> 2021;384(8):755-57. doi: 10.1056/NEJMe2024638 [published Online First: 2020/07/18]
606 607 608 609 610	18. Ranney ML, Griffeth V, Jha AK. Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic. <i>The New England</i> <i>journal of medicine</i> 2020;382(18):e41. doi: 10.1056/NEJMp2006141 [published Online First: 2020/03/27]
611	
612	
613	
614	
615	
616	
617	
618	

٤9 Figure Legends

20 21

22 Figure 1. ISPY COVID Trial Design. Hospitalized COVID-19 patients who require ≥6 L/min nasal oxygen or 23 more (COVID-19 status ≥5) are eligible for the trial. Patients or surrogates that meet master protocol 24 inclusion/exclusion are approached for willingness to participate in the Randomized Cohort of the trial. Those 25 that voice interest are randomized, and then approached with the agent specific consent. All patients in the 26 Randomized Cohort receive backbone therapy with or without an additional investigational agent. Enrolled 27 participants are followed for the assessment of the primary outcomes of resolution of severe COVID-19 and 28 mortality. Patients that are either not approached for the Randomized Cohort of the trial or decline individual 29 investigation agent consent are tracked in the observational cohort. 30

31 Figure 2. Patient Enrollment Flow into the ISPY COVID Platform Trial.

32 33 Figure 3. Modeling Recovery in the ISPY COVID Trial. The figure shows examples of trial data based on 34 simulations. Top panel: Posterior cumulative incidence and survival functions (solid lines) and 95% quantile 35 credible intervals (shaded area between dotted lines). Bottom panel: Medians (solid lines) and 95% quantile 36 credible intervals (shaded area between dotted lines) for the posterior distribution of the difference in the 37 Cumulative Incidence functions (Investigational Arm versus Control).

39 Figure 4. Daily Clinically Important Events Systematically Captured in Participants. Daily forms are 10 completed in ISPY participants relating to clinically important events occurring in the context of severe COVID-11 19. These events are then systematically reported across arms of the study for safety reports to the Data 12 Monitoring Committee.

Figure 5. Severe Laboratory Abnormalities Systematically Captured in Participants. Potentially 14 ł5 significant daily laboratory data entered by study coordinators is systematically captured, graded and reported back to the Data Monitoring Committee to evaluate safety. In this simulated example, Agent C appears to be 16 ŀ7 associated with increased creatinine, suggesting renal toxicity.

18 19

38

13

;0

51

;2







Prophylactic anticoagulation Therapeutic anticoagulation Shock on Antibiotics DIC DVT МІ PE Pneumothorax RRT Stroke Total vasopressors 100 75 50 25 8 0 Agent A Agent C Control

ARDS Related Clinical Event (% subject with at least one incidence)

Percent of subject with at least one incidence

Laboratory CTCAE v5.0 Grading (Grade 3 or 4) (% subject with at least one incidence)



